Real-world study of first-line therapy with aumolertinib for elderly patients with non-small cell lung cancer harboring EGFR mutation

Elderly non-small cell lung cancer (NSCLC) patients do not always benefit from standard treatments due to impaired organ function and/or multiple comorbidities. Our study aimed to determine the efficacy and safety of aumolertinib as a first-line therapy in NSCLC patients aged ≥65 and <65 years in clinical practice.We enrolled 100 patients with stage IIA-IVB epidermal growth factor receptor-mutant NSCLC who received aumolertinib alone as the first-line therapy. Efficacy and safety were compared between patients aged ≥65 and <65 years in different subgroups. The primary endpoint was the objective response rate (ORR). The secondary endpoints included progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and safety.Overall, ORR and DCR were 76% and 98%, respectively. ORR was 69.4% and 82.4% for patients aged ≥ 65 and < 65 years, respectively (P = .27), and DCR was 98% and 98%, respectively (P = .93). The median PFS was 23.2 months. The median PFS was 26.9 months and 18.3 months in the ≥65 and <65 years groups, respectively (P = .377, and the median OS of all patients was 31.7 months. The median OS was 33.7 months and 30.7 months in the ≥65 and <65 years groups, respectively (P = .851). Adverse events were not statistically different between the 2 groups.The efficacy and safety profile of aumolertinib as a first-line therapy in elderly patients with epidermal growth factor receptor-mutant NSCLC were similar to those observed in the younger subgroup.